Atrium Therapeutics, Inc.

NASDAQ:RNA

Biotechnology

Healthcare
$6.64 +1.28%

+$0.16 today

Market cap
$143.23M
Beta
0.42
P/E (TTM)
-3.3
EPS (TTM)
-$3.78
52W Low $11.40High $16.77

Volume 0.22M

Average 0.35M

RNA EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Atrium Therapeutics, Inc.NASDAQ: RNA

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA of -$16.48M in Q1 FY2026

Q1 FY2026 EBITDA was -$16.48M.

Context

  • EBITDA amounted to 410.9% of revenue in FY2025.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of -$55.48M (+27.5%) for the fiscal year ending Dec 2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$16.48M+65.6% QoQ
Last fiscal yearDec 2025
-$76.5M— YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year—+27.5%—
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(76.5M) USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How RNA compares with its peers on the latest reported figures

No competitor EBITDA figures are available to compare.

Atrium Therapeutics, Inc.

NASDAQ:RNA

Intrinsic Alpha fair value

Locked

Current Price

$6.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.